Is it Time to Dump Timber Pharmaceuticals Inc (TMBR) Stock After it Is Higher By 3.88% in a Week?

Tuesday, June 27, 2023 10:10 AM | InvestorsObserver Analysts

Mentioned in this article

Is it Time to Dump Timber Pharmaceuticals Inc (TMBR) Stock After it Is Higher By 3.88% in a Week?

Overall market sentiment has been high on Timber Pharmaceuticals Inc (TMBR) stock lately. TMBR receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Timber Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on TMBR!

See Full TMBR Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With TMBR Stock Today?

Timber Pharmaceuticals Inc (TMBR) stock is lower by -3.6% while the S&P 500 has risen 0.34% as of 10:02 AM on Tuesday, Jun 27. TMBR has fallen -$0.08 from the previous closing price of $2.22 on volume of 52,223 shares. Over the past year the S&P 500 has gained 11.37% while TMBR has fallen -85.76%. TMBR lost -$12.01 per share in the over the last 12 months. To screen for more stocks like Timber Pharmaceuticals Inc click here.

More About Timber Pharmaceuticals Inc

Timber Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. It is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis, facial angiofibromas in tuberous sclerosis complex, and scleroderma. The company's development pipeline includes TMB-001 (Topical Isotretinoin), TMB-002 (Topical Rapamycin), and TMB-003 (Topical / Subcutaneous ET-A Receptor Antagonist). Click Here to get the full Stock Report for Timber Pharmaceuticals Inc stock.